These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 17409863)

  • 1. Treatment of elderly non-small cell lung cancer patients with three different schedules of weekly paclitaxel in combination with carboplatin: subanalysis of a randomized trial.
    Ramalingam S; Barstis J; Perry MC; La Rocca RV; Nattam SR; Rinaldi D; Clark R; Mills GM; Belani CP
    J Thorac Oncol; 2006 Mar; 1(3):240-4. PubMed ID: 17409863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer.
    Ramalingam S; Perry MC; La Rocca RV; Rinaldi D; Gable PS; Tester WJ; Belani CP
    Cancer; 2008 Aug; 113(3):542-6. PubMed ID: 18512224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weekly regimen of paclitaxel and carboplatin as first-line chemotherapy in elderly patients with stage IIIB-IV non small cell lung cancer (NSCLC): results of a phase II study.
    Rozzi A; Nardoni C; Corona M; Restuccia MR; Falbo T; Lanzetta G
    J Chemother; 2010 Dec; 22(6):419-23. PubMed ID: 21303751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non-small-cell lung cancer.
    Sakakibara T; Inoue A; Sugawara S; Maemondo M; Ishida T; Usui K; Abe T; Kanbe M; Watanabe H; Saijo Y; Nukiwa T
    Ann Oncol; 2010 Apr; 21(4):795-799. PubMed ID: 19815651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer.
    Okamoto I; Moriyama E; Fujii S; Kishi H; Nomura M; Goto E; Kiyofuji C; Imamura F; Mori T; Matsumoto M
    Jpn J Clin Oncol; 2005 Apr; 35(4):188-94. PubMed ID: 15845567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer.
    Socinski MA; Manikhas GM; Stroyakovsky DL; Makhson AN; Cheporov SV; Orlov SV; Yablonsky PK; Bhar P; Iglesias J
    J Thorac Oncol; 2010 Jun; 5(6):852-61. PubMed ID: 20521351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.
    Belani CP; Ramalingam S; Perry MC; LaRocca RV; Rinaldi D; Gable PS; Tester WJ
    J Clin Oncol; 2008 Jan; 26(3):468-73. PubMed ID: 18202422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter randomized trial for stage IIIB/IV non-small-cell lung cancer using every-3-week versus weekly paclitaxel/carboplatin.
    Schuette W; Blankenburg T; Guschall W; Dittrich I; Schroeder M; Schweisfurth H; Chemaissani A; Schumann C; Dickgreber N; Appel T; Ukena D
    Clin Lung Cancer; 2006 Mar; 7(5):338-43. PubMed ID: 16640806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two different carboplatin and weekly paclitaxel schedule in elderly advanced non-small cell lung cancer patients.
    Kıvrak Salim D; Akın Telli T; Tatlı AM; Kılıçkap S; Yumuk PF
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1137-1145. PubMed ID: 30972457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Phase II Study of Weekly Paclitaxel plus Carboplatin Versus Biweekly Paclitaxel plus Carboplatin for Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer.
    Takayama K; Ichiki M; Tokunaga S; Inoue K; Kawasaki M; Uchino J; Nakanishi Y
    Oncologist; 2019 Nov; 24(11):1420-e1010. PubMed ID: 31332099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel.
    Hensing TA; Peterman AH; Schell MJ; Lee JH; Socinski MA
    Cancer; 2003 Aug; 98(4):779-88. PubMed ID: 12910523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
    Marsland TA; Garfield DH; Khan MM; Look RM; Boehm KA; Asmar L
    Lung Cancer; 2005 Jan; 47(1):111-20. PubMed ID: 15603861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer.
    Kelly K; Pan Z; Murphy J; Huffman DH; Bunn PA
    Clin Cancer Res; 1997 Jul; 3(7):1117-23. PubMed ID: 9815791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II trial comparing carboplatin plus weekly paclitaxel and docetaxel alone in elderly patients with advanced non-small cell lung cancer: north japan lung cancer group trial 0801.
    Maemondo M; Inoue A; Sugawara S; Harada T; Minegishi Y; Usui K; Miwa K; Morikawa N; Kambe M; Ube K; Watanabe K; Ishimoto O; Sakakibara T; Gemma A; Nukiwa T
    Oncologist; 2014 Apr; 19(4):352-3. PubMed ID: 24682465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation.
    Belani CP; Barstis J; Perry MC; La Rocca RV; Nattam SR; Rinaldi D; Clark R; Mills GM
    J Clin Oncol; 2003 Aug; 21(15):2933-9. PubMed ID: 12885812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel by 1-h infusion in combination with carboplatin in advanced non-small cell lung carcinoma (NSCLC).
    Langer CJ; McAleer CA; Bonjo CA; Litwin S; Millenson M; Kosierowski R; Blankstein K; Alexander R; Ozols RF
    Eur J Cancer; 2000 Jan; 36(2):183-93. PubMed ID: 10741276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Open-Label Randomized Controlled Trial Comparing the Efficacy and Safety of Pemetrexed-Carboplatin versus (Weekly) Paclitaxel-Carboplatin as First-Line Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer.
    Yadav A; Malik PS; Khurana S; Jain D; Vishnubhatla S; Yadav M; Pathy S; Mohan A; Kumar L
    Oncology; 2021; 99(6):389-396. PubMed ID: 33735884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer.
    Yumuk PF; Turhal NS; Gumus M; Hatabay NF; Turken O; Ozkan A; Salepci T; Aliustaoglu M; Ahiskali R
    BMC Cancer; 2005 Jan; 5():10. PubMed ID: 15667664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combination chemotherapy with carboplatin and weekly Paclitaxel in patients with advanced non-small cell lung cancer].
    Hashizume T; Ogura T; Kozawa S; Yamaguchi N; Hayashi M; Nakamura M; Miyazawa N; Watanuki Y; Takahashi H
    Gan To Kagaku Ryoho; 2006 Apr; 33(4):471-5. PubMed ID: 16612156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301.
    Miyauchi E; Inoue A; Usui K; Sugawara S; Maemondo M; Saito H; Fujita Y; Kato T; Suzuki T; Harada T; Watanabe H; Nakagawa T; Ichinose M
    Oncologist; 2017 Jun; 22(6):640-e59. PubMed ID: 28526722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.